Adoptive immunotherapy against ovarian cancer

Mittica, Gloria; Capellero, Sonia; Genta, Sofia; Cagnazzo, Celeste; Aglietta, Massimo; Sangiolo, Dario; Valabrega, Giorgio

doi:10.1186/s13048-016-0236-9

Cited by 37 publications

(25 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natural killer (NK) cells are involved in innate immunity and tumor surveillance; they also have the ability to recognize MHC class I or class I-like molecules on target cells through a unique class of receptors 34. NK cells are capable of exerting anti-tumor activity and lysing tumor cells without prior sensitization in an HLA-unrestricted way in contrast to TILs, for example.…”

Section: Cell-based Therapymentioning

confidence: 99%

Immunotherapy in ovarian cancer: fake news or the real deal?

Marth¹,

Wieser

Tsibulak

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

Cancer immunotherapy has emerged as one of the most promising approaches in oncology, and comprises the activation of the immune system to induce tumor immune surveillance or to reverse the tumor immune escape. Different therapeutic strategies for ovarian carcinoma have evolved over the years. Already 30 years ago, the first clinical studies focused on modulating the tumor cytokine network with special attention to interferon-mediated immune responses. With the exploration of specific tumor antigens such as NY-ESO-1, which is expressed in ovarian carcinoma and other malignancies, the development of therapeutic cancer vaccines has been pursued initiating the era of personalized anti-cancer medicine. Almost at the same time, the adoptive transfer of genetically modified autologous tumor-reactive T-cells occurred, but response rates in ovarian carcinoma were disappointing. Today, probably the most promising therapeutic approach in this context is the blockade of immune checkpoints, such as programed cell death protein 1 (PD-1) and one of its ligands (PD-L1) or cytotoxic T-cell lymphocyte-associated antigen 4 (CTLA-4), which has demonstrated impressive response rates in malignant melanoma and non-small cell lung cancer. Despite increasing availability of treatment approaches that target tumor immune surveillance in ovarian carcinoma, selecting patient groups that particularly benefit from these treatment modalities is clinically challenging as predictive biomarkers are lacking. Here, we summarize different immunotherapy approaches in ovarian cancer and discuss why immunotherapy in ovarian cancer is still in its infancy.

show abstract

Section: Cell-based Therapymentioning

confidence: 99%

Immunotherapy in ovarian cancer: fake news or the real deal?

Marth¹,

Wieser

Tsibulak

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Secondly, this also evidences the main location of resistant tumor EOC cells is within the peritoneal cavity thus representing a unique opportunity to target and eliminate them by local administrations using selected immune effectors. 4 This unique therapeutic opportunity is further supported by the results of studies that reported the feasibility and the clinical benefits of intraperitoneal adoptive transfers of lymphocytes (e.g., tumor-infiltrative T and Natural Killer (NK) lymphocytes) (see 5 for a review). Importantly, they suggested that their clinical efficacy could be enhanced by optimizing associations and positioning with standard therapeutic lines (e.g., maintenance).…”

Section: Introductionmentioning

confidence: 97%

Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo

et al. 2019

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) represents 5% of human gynecologic cancers in the world, is heterogeneous and highly invasive with a dismal prognosis (5 year-survival rate <35%). Diagnosis of EOC is frequently made at advanced stages and, despite aggressive treatments combining surgery and chemotherapy, fatal relapse rapidly occurs and is accompanied by a peritoneal carcinosis. In this context, novel therapeutical advances are urgently required. Adoptive transfer(s) of immune effector cells, including allogeneic human Vγ9Vδ2 T lymphocytes, represent attractive targets for efficiently and safely tracking tissue-invading tumor cells and controlling tumor dissemination in the organism. Our study describes the establishment of robust and physiological orthotopic model of human EOC in mouse, that includes surgical resection (ovariectomy) and chemotherapy, which are ineluctably accompanied by a fatal peritoneal carcinosis recurrence. Through a complementary set of in vitro and in vivo experiments, we provide here a preclinical proof of interest of the antitumor efficiency of adoptive transfers of allogeneic human Vγ9Vδ2 T lymphocytes against EOC, in association with surgical debulking and standard chemotherapies (i.e., taxanes and platinum salts). Moreover, our results indicate that chemoand immunotherapies can be combined to improve the antitumor efficiency of immunotherapeutic lines. Altogether, these results further pave the way for next-generation antitumor immunotherapies, based on local administrations of human allogeneic human Vγ9Vδ2 T lymphocytes, in association with standard treatments.

show abstract

“…Moreover, IFN-g is the major cytokine secreted by NK cells and has been shown to induce the permanent arrest of the growth of melanoma cells [77]. Ovarian cancer cells have high expression of MICA/B and ULBPs, which can activate NK cells through the active receptor NKG2D [51]. However, immunotherapies, which use NK cells for melanoma, ovarian cancer, and other solid tumors, can control disease progression but limitedly improve or abate disease [76,[78][79][80][81][82][83].…”

Section: Solid Tumorsmentioning

confidence: 99%

“…Immunotherapy using NK cells is a panspecific ACT immunotherapy that does not rely on the recognition of HLA-mediated tumor antigen [51]. Autologous and allogeneic NK cells can be both used in ACT immunotherapy because their safety and tolerability have been proven [52][53][54].…”

Section: Contribution Of Nk Cells To Cellular Immunotherapymentioning

confidence: 99%

Challenges of NK cell-based immunotherapy in the new era

2018

View full text Add to dashboard Cite

Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.

show abstract

Adoptive immunotherapy against ovarian cancer

Cited by 37 publications

References 80 publications

Immunotherapy in ovarian cancer: fake news or the real deal?

Immunotherapy in ovarian cancer: fake news or the real deal?

Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo

Challenges of NK cell-based immunotherapy in the new era

Contact Info

Product

Resources

About